Analyst Reiterates Buy Rating on ZyVersa Therapeutics with Revised Price Target
On March 12, 2024, analyst Ed Arce from HC Wainwright & Co. reiterated his Buy rating on ZyVersa Therapeutics (NASDAQ: ...
© 2024 Stocks Today
Tag: ZVSA
Developing a Promising Therapeutic Option for ObesityRelated Inflammation Inflammasome ASC Inhibitor IC 100
Obesity is a prevalent global issue, affecting millions of individuals worldwide. It is characterized by chronic inflammation, which can lead ...
ZyVersa Therapeutics Makes Stunning Comeback After Trading Halt
On February 26, 2024, ZyVersa Therapeutics made a remarkable comeback as trading resumed following a circuit breaker halt, resulting in ...
Unveiling the Role of Inflammation and ASC Specks in Neurological Diseases A Milestone in Therapeutic Advancements
On February 14, 2024, a groundbreaking review article was unveiled by ZyVersa Therapeutics, shedding light on a crucial aspect of ...
Inflammasome Activation Linked to Brain Metastasis in TripleNegative Breast Cancer
On January 17, 2024, ZyVersa Therapeutics, Inc. shed light on a groundbreaking study that establishes a connection between inflammasome activation ...
Don't Miss It
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
Office Real Estate Investment Trusts REITs WellPositioned for ReturntoWork Trend
-
RTW Investments LP Reduces Stake in Illumina, Inc. (NASDAQ:ILMN) as Company Exceeds Earnings Expectations and Reports Revenue Growth